In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTCTRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEPDOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIVPRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEPPresenters:Jean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and lariboisièreParis, FranceJoseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program: https://bit.ly/3BBaZvJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related